Location: Jacksonville (Headquarters)

3550 University Blvd South

Suite #101

Jacksonville, FL 32216

Tel: (904) 854-1354

Fax:

A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation

Location(s): Jacksonville (Headquarters)

Condition: Atrial Fibrillation

A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus

Location(s): Jacksonville (Headquarters), Jacksonville - Southside

Condition: Overweight / Obesity, Type 2 Diabetes

A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 Diabetes

Location(s): Jacksonville (Headquarters), Jacksonville - Southside

Condition: Overweight / Obesity

Placebo Controlled, Double Blind, Randomized Cardiovascular Outcome Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With ASCVD Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Jacksonville - Southside, Lake City, St. Augustine

Condition: Heart / Cardiovascular Disease, High Cholesterol

Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

Location(s): Jacksonville (Headquarters), Jacksonville - Southside, Lake City, Macon, St. Augustine

Condition: Heart / Cardiovascular Disease, High Cholesterol

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.

Location(s): Jacksonville (Headquarters), Jacksonville - Southside

Condition: Overweight / Obesity, Type 2 Diabetes

A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Jacksonville - Southside, Lake City, Macon, St. Augustine

Condition: Heart / Cardiovascular Disease

Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation

Location(s): Jacksonville (Headquarters)

Condition: Heart / Cardiovascular Disease, Kidney Disease

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

Location(s): Jacksonville (Headquarters), St. Augustine

Condition: Heart Failure